Published in Curr Cancer Drug Targets on May 01, 2010
Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res (2011) 2.85
The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer. Oncotarget (2015) 1.78
An analogy between the evolution of drug resistance in bacterial communities and malignant tissues. Nat Rev Cancer (2011) 1.58
An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death Dis (2013) 1.49
Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis. Neuro Oncol (2013) 1.32
Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One (2012) 1.31
Oxidative stress, tumor microenvironment, and metabolic reprogramming: a diabolic liaison. Int J Cell Biol (2012) 1.29
Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol (2013) 1.29
Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. Mol Cancer (2013) 1.27
Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules. Proc Natl Acad Sci U S A (2013) 1.23
Immunohistochemical detection of epithelialmesenchymal transition associated with stemness phenotype in anaplastic thyroid carcinoma. Int J Clin Exp Pathol (2010) 1.10
The sensors and regulators of cell-matrix surveillance in anoikis resistance of tumors. Int J Cancer (2010) 1.08
The network of epithelial-mesenchymal transition: potential new targets for tumor resistance. J Cancer Res Clin Oncol (2014) 1.04
T-box transcription factor Brachyury expression is correlated with epithelial-mesenchymal transition and lymph node metastasis in oral squamous cell carcinoma. Int J Oncol (2012) 1.02
Attributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary. J Ovarian Res (2012) 1.02
Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67. Breast Cancer Res (2011) 1.01
Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer. Br J Cancer (2013) 0.98
Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden. Front Oncol (2014) 0.98
The T-box transcription factor Brachyury regulates epithelial-mesenchymal transition in association with cancer stem-like cells in adenoid cystic carcinoma cells. BMC Cancer (2012) 0.95
Tumor-derived exosomes in cancer progression and treatment failure. Oncotarget (2015) 0.94
Ovarian cancer stem cells: a new target for cancer therapy. Biomed Res Int (2013) 0.92
Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability. Science (2016) 0.92
Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer. Sci Rep (2015) 0.91
Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. BMC Cancer (2014) 0.91
Withaferin a alone and in combination with cisplatin suppresses growth and metastasis of ovarian cancer by targeting putative cancer stem cells. PLoS One (2014) 0.87
Notch signaling in serous ovarian cancer. J Ovarian Res (2014) 0.87
Expression of cancer stem cell markers and epithelial-mesenchymal transition-related factors in anaplastic thyroid carcinoma. Int J Clin Exp Pathol (2015) 0.86
Cyclin D1 affects epithelial-mesenchymal transition in epithelial ovarian cancer stem cell-like cells. Onco Targets Ther (2013) 0.86
Down-regulation of HtrA1 activates the epithelial-mesenchymal transition and ATM DNA damage response pathways. PLoS One (2012) 0.85
The role of nuclear β-catenin accumulation in the Twist2-induced ovarian cancer EMT. PLoS One (2013) 0.85
Mechanisms of therapeutic resistance in cancer (stem) cells with emphasis on thyroid cancer cells. Front Endocrinol (Lausanne) (2014) 0.85
Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles. Oncotarget (2014) 0.84
Ascites-induced shift along epithelial-mesenchymal spectrum in ovarian cancer cells: enhancement of their invasive behavior partly dependant on αv integrins. Clin Exp Metastasis (2014) 0.84
Ginsenoside 20(S)-Rg3 targets HIF-1α to block hypoxia-induced epithelial-mesenchymal transition in ovarian cancer cells. PLoS One (2014) 0.84
Understanding and overcoming chemoresistance in ovarian cancer: emerging role of the endothelin axis. Curr Oncol (2012) 0.83
TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling. Sci Rep (2016) 0.83
Spontaneous spheroid budding from monolayers: a potential contribution to ovarian cancer dissemination. Biol Open (2012) 0.82
Overexpression of CD157 contributes to epithelial ovarian cancer progression by promoting mesenchymal differentiation. PLoS One (2012) 0.82
Downregulation of serine protease HTRA1 is associated with poor survival in breast cancer. PLoS One (2013) 0.82
Extracts from Curcuma zedoaria Inhibit Proliferation of Human Breast Cancer Cell MDA-MB-231 In Vitro. Evid Based Complement Alternat Med (2014) 0.82
Knockdown of the T-box transcription factor Brachyury increases sensitivity of adenoid cystic carcinoma cells to chemotherapy and radiation in vitro: implications for a new therapeutic principle. Int J Oncol (2014) 0.80
Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood. Cell Mol Bioeng (2015) 0.80
Mesenchymal stem-like cells isolated from human esophageal carcinoma and adjacent non-cancerous tissues. Oncol Lett (2012) 0.80
Failure of anti tumor-derived endothelial cell immunotherapy depends on augmentation of tumor hypoxia. Oncotarget (2014) 0.79
Suppression of cancer stemness p21-regulating mRNA and microRNA signatures in recurrent ovarian cancer patient samples. J Ovarian Res (2012) 0.79
Metformin against cancer stem cells through the modulation of energy metabolism: special considerations on ovarian cancer. Biomed Res Int (2014) 0.79
Enhanced breast cancer therapy with nsPEFs and low concentrations of gemcitabine. Cancer Cell Int (2014) 0.79
Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells. Sci Rep (2016) 0.78
Epimorphin-induced MET sensitizes ovarian cancer cells to platinum. PLoS One (2013) 0.78
The impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasis. Carcinogenesis (2015) 0.77
Ets-1 regulates intracellular glutathione levels: key target for resistant ovarian cancer. Mol Cancer (2013) 0.77
Natural products as potential cancer therapy enhancers: A preclinical update. SAGE Open Med (2014) 0.77
Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells. Clin Exp Metastasis (2016) 0.77
miR-203 Functions as a Tumor Suppressor by Inhibiting Epithelial to Mesenchymal Transition in Ovarian Cancer. J Cancer Sci Ther (2016) 0.77
Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells. Sci Rep (2017) 0.76
Hybrid-polymerase chain reaction to identify novel target genes of miR-134 in paclitaxel resistant human ovarian carcinoma cells. Oncol Lett (2015) 0.76
The molecular mechanisms of chemoresistance in cancers. Oncotarget (2017) 0.75
Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML). PLoS One (2015) 0.75
Vitronectin in the ascites of human ovarian carcinoma acts as a potent chemoattractant for ovarian carcinoma: Implication for metastasis by cancer stem cells. J Cancer Stem Cell Res (2016) 0.75
Anti-proliferative activity and cell cycle arrest induced by evodiamine on paclitaxel-sensitive and -resistant human ovarian cancer cells. Sci Rep (2015) 0.75
SUSD2 expression in high-grade serous ovarian cancer correlates with increased patient survival and defective mesothelial clearance. Oncogenesis (2016) 0.75
Lentiviral CRISPR/Cas9 vector mediated miR-21 gene editing inhibits the epithelial to mesenchymal transition in ovarian cancer cells. J Cancer (2017) 0.75
The effects of DNA methylation and epigenetic factors on the expression of CD133 in ovarian cancers. J Ovarian Res (2012) 0.75
Ovarian cancer stem cells: still an elusive entity? Mol Cancer (2017) 0.75
Oxidative stress, epigenetics, and cancer stem cells in arsenic carcinogenesis and prevention. Curr Pharmacol Rep (2016) 0.75
Targeting mesenchymal exaptation to mitigate tumor growth. Cell Cycle (2011) 0.75
p27(Kip1) enforces maintenance of quiescence in the mammalian ear and the pituitary gland. Cell Cycle (2011) 0.75
Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer. Oncotarget (2016) 0.75
Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget (2016) 0.75
Epithelial-mesenchymal transition of ovarian cancer cells is sustained by Rac1 through simultaneous activation of MEK1/2 and Src signaling pathways. Oncogene (2016) 0.75
Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets. Ann Transl Med (2016) 0.75
Harnessing protein kinase A activation to induce mesenchymal-epithelial programs to eliminate chemoresistant, tumor-initiating breast cancer cells. Transl Cancer Res (2016) 0.75
Identification of common oncogenic and early developmental pathways in the ovarian carcinomas controlling by distinct prognostically significant microRNA subsets. BMC Genomics (2017) 0.75
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst (2004) 2.79
Chapter 8: Screening for cervical cancer in developing countries. Vaccine (2006) 2.35
Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J Neurosci (2011) 2.31
A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res (2005) 2.24
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer (2011) 2.09
Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J Cell Biochem (2011) 1.60
A new prognostic model for FIGO stage 1 epithelial ovarian cancer. Gynecol Oncol (2006) 1.43
LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer Res (2012) 1.39
Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin Exp Metastasis (2005) 1.30
An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum. Proteomics (2003) 1.30
Nomogram to predict the probability of relapse in patients diagnosed with borderline ovarian tumors. Int J Gynecol Cancer (2013) 1.25
Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine (2004) 1.12
Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. J Cell Biochem (2013) 1.10
First-line therapy in ovarian cancer trials. Int J Gynecol Cancer (2011) 1.03
Pontocerebellar hypoplasia type 6: A British case with PEHO-like features. Am J Med Genet A (2010) 1.02
Attributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary. J Ovarian Res (2012) 1.02
Microwave tomography of extremities: 2. Functional fused imaging of flow reduction and simulated compartment syndrome. Phys Med Biol (2011) 1.01
The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol (2006) 1.00
Single coronary artery. J Am Coll Cardiol (2009) 1.00
Microwave tomography of extremities: 1. Dedicated 2D system and physiological signatures. Phys Med Biol (2011) 0.99
Epidermal growth factor-induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of alpha6beta1 integrin. Int J Biochem Cell Biol (2008) 0.99
Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study. Int J Gynecol Cancer (2010) 0.96
Neuroendocrine and behavioral effects of embryonic exposure to endocrine disrupting chemicals in birds. Brain Res Rev (2007) 0.95
Association between alphavbeta6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer. J Cell Biochem (2002) 0.93
Graft site and gonadotrophin stimulation influences the number and quality of oocytes from murine ovarian tissue grafts. Reproduction (2006) 0.92
Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. BMC Cancer (2014) 0.91
Outcome in women with no endocervical component on cervical cytology after treatment for high-grade cervical dysplasia. Aust N Z J Obstet Gynaecol (2009) 0.88
FIGO Cancer Report 2012. Int J Gynaecol Obstet (2012) 0.87
Prognostic value of elevated preoperative serum CA125 in ovarian tumors of low malignant potential: a multinational collaborative study (ANZGOG0801). Gynecol Oncol (2012) 0.87
Anxiety and depression symptoms in the 2 years following diagnosis of breast or gynaecologic cancer: prevalence, course and determinants of outcome. Support Care Cancer (2015) 0.86
Proteomic profiling of proteins associated with urokinase plasminogen activator receptor in a colon cancer cell line using an antisense approach. Proteomics (2003) 0.85
An investigation into the relationship between vigabatrin, movement disorders, and brain magnetic resonance imaging abnormalities in children with infantile spasms. Dev Med Child Neurol (2013) 0.84
Incidence of microsatellite instability in synchronous tumors of the ovary and endometrium. Clin Cancer Res (2003) 0.84
Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment. Clin Immunol (2013) 0.84
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors). Int J Gynecol Cancer (2014) 0.84
Screening for depression and anxiety in women with breast and gynaecologic cancer: course and prevalence of morbidity over 12 months. Psychooncology (2013) 0.83
A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. Gynecol Oncol (2004) 0.83
Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009. Int J Gynecol Cancer (2010) 0.83
Re-transplantation after bortezomib-based therapy. Br J Haematol (2011) 0.82
Should the Pap smear be repeated at the first colposcopy visit? Aust N Z J Obstet Gynaecol (2005) 0.82
Cotyledonoid dissecting leiomyoma. Pathology (2003) 0.82
Excessive bleeding and transfusion in a prior cardiac surgery is associated with excessive bleeding and transfusion in the next surgery. Anesth Analg (2006) 0.82
Persistent trophoblast disease following partial molar pregnancy. Aust N Z J Obstet Gynaecol (2006) 0.82
Complementary medicine use by Australian women with gynaecological cancer. Psychooncology (2006) 0.82
Transforming growth factor-beta: its role in ovarian follicle development. Reproduction (2008) 0.81
Sister Society Meeting on Global Education Development and Collaboration: Meeting Report. Int J Gynecol Cancer (2016) 0.81
Hereditary gynecologic cancers. Int J Gynaecol Obstet (2013) 0.80
Question 1: Should steroids be used to treat abdominal pain caused by Henoch-Schonlein purpura? Arch Dis Child (2012) 0.80
Guidelines following hydatidiform mole: a reappraisal. Aust N Z J Obstet Gynaecol (2006) 0.79
Focus on TGF-beta signalling. Reproduction (2006) 0.78
Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide. Transfusion (2014) 0.78
Women with low-grade abnormalities on Pap smear should be referred for colposcopy. Aust N Z J Obstet Gynaecol (2004) 0.78
Findings and Outcomes in a Prevaccination Cohort of Women Younger Than 25 Years Attending a Tertiary Colposcopy Service. J Low Genit Tract Dis (2016) 0.77
Glycosylation of pilin and nonpilin protein constructs by Pseudomonas aeruginosa 1244. J Bacteriol (2010) 0.77
Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era. Int J Gynecol Cancer (2013) 0.77
Substantially modified ratios of effector to regulatory T cells during chemotherapy in ovarian cancer patients return to pre-treatment levels at completion: implications for immunotherapy. Cancers (Basel) (2012) 0.77
"Like roulette": Australian women's explanations of gynecological cancers. Soc Sci Med (2005) 0.77
Reproductive consequences of EDCs in birds: what do laboratory effects mean in field species? Neurotoxicol Teratol (2002) 0.76
Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations. J Transl Med (2014) 0.75
Partnership for Healthier Asians: Disseminating Evidence-Based Practices in Asian-American Communities Using a Market-Oriented and Multilevel Approach. JMIR Res Protoc (2016) 0.75
Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer. Nature (2015) 0.75
Risk stratification for free. Br J Gen Pract (2016) 0.75
The effect of an extended flexor carpi radialis approach on blood flow to the distal radius: a cadaveric study. Orthopedics (2005) 0.75
Temporal fossa intra-extracranial dumbbell schwannoma. Br J Neurosurg (2010) 0.75
Challenging Salpingectomy as a Risk-Reducing Measure for Ovarian Cancer: Histopathological Analysis of the Tubo-Ovarian Interface in Women Undergoing Risk-Reducing Salpingo-oophorectomy. Int J Gynecol Cancer (2017) 0.75
Alopecia neoplastica caused by desmoplastic melanoma. Australas J Dermatol (2003) 0.75
'He's telling us something'. Anthropol Med (2004) 0.75
Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database Syst Rev (2016) 0.75
Is colposcopy needed following laser ablation for dysplasia? Aust N Z J Obstet Gynaecol (2006) 0.75
Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases. Int J Gynecol Cancer (2016) 0.75
Infertility Treatment Act or forced sterilisation program?: comment. Med J Aust (2009) 0.75
Benign endocervical cystic glandular change mimicking minimal deviation adenocarcinoma of the cervix on magnetic resonance imaging: a case report. Aust N Z J Obstet Gynaecol (2004) 0.75
Conventional approach to glucose management for diabetic patients undergoing coronary artery bypass surgery. Perfusion (2002) 0.75
Concussion symptoms in youth motocross riders: a prospective, observational study. J Neurosurg Pediatr (2015) 0.75
Treatment decisions: a qualitative study with women with gynaecological cancer. Aust N Z J Obstet Gynaecol (2006) 0.75
Embodied changes and the search for gynecological cancer diagnosis. Med Anthropol Q (2004) 0.75
Maxillomandibular distraction osteogenesis advancement for the treatment of obstructive sleep apnea. J Oral Maxillofac Surg (2007) 0.75